Global Diabetes Insulin Delivery Pens Market 2011-2018 & 2025 with Analysis of Key Companies – Biocon, Eli Lilly, Novo Nordisk, Owen Mumford, Sanofi & Ypsomed

Dublin, Sept. 21, 2018 (GLOBE NEWSWIRE) -- The "Diabetes Insulin Delivery Pens Market Research Report 2018" report has been added to ResearchAndMarkets.com's offering.

Diabetes Insulin Delivery Pen market will surpass US$ 14.4 Billion by 2025

Market growth can be attributed to factors such as growing diabetes patient population, high adoption rate, user-friendly design, rising popularity among consumers, help avoid over/under-dosing of insulin, rising market demand for human insulin analogs, government support and technological advancements in the field of insulin pen devices

Diabetes Insulin Delivery Pens Market Research Report 2018 presents an in-depth assessment of the diabetes insulin delivery pen market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook for diabetes insulin delivery pen market. The report includes historical data from 2011 to 2017 and forecasts until 2025.

The report contains a granular analysis of the present industry situations, market demands, reveal facts on the market size, insulin pen volume, revenues for insulin pen and its segments reusable and disposable insulin pen and illustrative forecast to 2025. It also provides an all-round analysis of an overall number of patients with diabetes and insulin users. A comprehensive analysis has been done on market share of diabetes insulin delivery pen segment and countries-based market. The report also explores detailed description of growth drivers and inhibitors of the diabetes insulin delivery pens market.

The superior geographic segments are identified in the report, which also studies the prospects showcased by the emerging markets. It covers the United States, United Kingdom, France, Italy, Spain, Germany, Japan, China, India and Brazil from 2011 to 2017 and forecasts to 2025.

The report concludes with the profiles of major players in the diabetes insulin delivery pens market. The key market players are evaluated on various parameters such as company overview, product portfolios and the recent development of the diabetes insulin delivery pens market.

Key Topics Covered:

1. Executive Summary

2. Diabetes Insulin Delivery Pen Users (Volume), 2011 - 2025
2.1 Diabetes Reusable (Cartridge) Insulin Delivery Pen Users (Volume), 2011 - 2025
2.2 Diabetes Prefilled (Disposable) Insulin Delivery Pen Users (Volume), 2011 - 2025

3. Diabetes Insulin Delivery Pen Market Size & Analysis (Value) 2011-2025
3.1 Diabetes Reusable (Cartridge) Insulin Delivery Pen Market (Value), 2011-2025
3.2 Diabetes Prefilled (Disposable) Insulin Delivery Pen Market (Value), 2011-2025

4. Diabetes Insulin Delivery Pen Market Share, By Users (%), 2011 - 2025
4.1 Diabetes Reusable (Cartridge) Insulin Delivery Pen Market Share, By Users (%)2011 - 2025
4.2 Diabetes Prefilled (Disposable) Insulin Delivery Pen Market Share, By Users (%), 2011 - 2025

5. Diabetes Insulin Delivery Pen Market Share (%), 2011 - 2025
5.1 Diabtes Reusable (Cartridge) Insulin Delivery Pen Market Share (%), 2011 - 2025
5.2 Diabetes Prefilled (Disposable) Insulin Delivery Pen Market Share (%), 2011 - 2025

6. Key Market Drivers & Inhibitors of the Diabetes Insulin Delivery Pen Market
6.1 Market Drivers
6.2 Market Inhibitors

7. Diabetes Insulin Delivery Pen Market & Forecast (2011 - 2025) - Geographical Landscape
7.1 United States
7.2 Germany
7.3 France
7.4 Italy
7.5 Spain
7.6 United Kingdom
7.7 Japan
7.8 China
7.9 India
7.10 Brazil

8. Key Companies Analysis

  • Biocon Ltd
  • Eli Lilly
  • Novo Nordisk
  • Owen Mumford
  • Sanofi
  • Ypsomed

For more information about this report visit https://www.researchandmarkets.com/research/dlnmrg/global_diabetes?w=12


CONTACT: 
CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Diabetes Devices , Endocrine and Metabolic Disorders Drugs, Endocrinology 

Ads